معرفی
Anan Yaghmur is an Associate Professor in Pharmaceutical Physical and Analytical Chemistry at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen. His research focuses on the development of lipid-based nanostructured drug delivery systems, particularly cubosomes and hexosomes, with applications in targeted drug delivery and biofilm prevention. He leads the Cubosome and Hexosome Nanomedicines (CH-NANO) research group and maintains active collaborations with institutions across Europe and Asia.
His research interests center on designing and characterizing nanomedicines using liquid crystalline phases, with specific expertise in cubosomes and hexosomes as self-assembled drug nanocarriers. He investigates the structural behavior of these systems under biological conditions, focusing on how drug loading affects internal nanostructures and interactions with biological environments. Current research includes lipid-based nano-structured drug delivery systems for colorectal cancer therapy, in situ characterization of liquid crystalline drug formulations, and developing liquid crystalline coatings to combat implant-associated biofilm infections. His work combines advanced characterization techniques like SAXS with microfluidic synthesis approaches to create tunable nanocarriers.
His recent publications highlight trends in developing antibiotic-free antimicrobial systems, omega-3 fatty acid nanocarriers, and pH-responsive drug delivery platforms. These works demonstrate increasing focus on translational applications, particularly in cancer therapy, biofilm prevention, and nutraceutical delivery. The research shows strong interdisciplinary collaboration, frequently combining pharmaceutical science with materials engineering and microbiology.
- Årets Underviser 2011 (Teacher of the Year award from Faculty of Health and Medical Sciences)
- Lise-Meitner Fellowship from Austrian Science Funds (2003-2004)
Yaghmur actively supervises 7 PhD students and multiple postdocs across projects funded by major organizations including the Danish Council for Independent Research, Novo Nordisk Foundation, and Marie Skłodowska-Curie Fellowships. His current major grants include the OMEGA project (2024-2028) targeting hepatic stellate cells with omega-3 nanocarriers and the MICNANO project (2023-2026) developing microfluidic synthesis for colorectal cancer therapy. His research group operates the CH-NANO laboratory at the University of Copenhagen, which specializes in structural characterization of lipid-based nanocarriers using synchrotron techniques and microfluidic platforms.
